Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/27171
Başlık: Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: A single center phase II study
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Bilim Dalı.
0000-0002-9732-5340
0000-0003-2501-3097
Kanat, Özkan
Evrensel, Türkkan
Kurt, Ender
Demiray, Mutlu
Gönüllü, Güzin
Arslan, Murat
Manavoğlu, Osman
AAJ-1027-2021
M-8060-2019
55881548500
6603942124
7006207332
6603631569
6506410014
57197925370
6602587152
Anahtar kelimeler: Oncology
Chemotherapy
Gemcitabine
5-fluorouracil
Pancreatic cancer
High-dose leucovorin
Tract cancer
Trial
Adenocarcinoma
Chemotherapy
Fluorouracil
Yayın Tarihi: 2004
Yayıncı: Sage Publications Ltd
Atıf: Kanat, Ö. vd. (2004). “Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: A single center phase II study”. Tumori, 90(2), 192-195.
Özet: Aim: To determine the activity and toxicity of a combination of weekly gemcitabine and 5-fluorouracil bolus intravenously in patients with metastatic pancreatic cancer. Patients and methods: Twenty-one patients with previously untreated metastatic pancreatic cancer were included in this phase II study. The schedule was gemcitabine (1000 mg/m(2) iv) and 5-fluorouracil (500 mg/m(2) bolus iv) weekly for 3 weeks every month. Results: Four patients (19%) achieved a partial response and three stable disease. A clinical benefit was obtained in 7 patients (33%). Median survival for all the patients was 6 months. The treatment was well tolerated and toxicity was mild. WHO grade 3 leukopenia occurred in 2 (9.5%) patients, grade 3 anemia in 4 (19%) patients, grade 3-4 thrombocytopenia in 4 (190%) patients, grade 1 diarrhea in 1 (4.7%) patient and grade 1 mucositis in 3 (14.2%) patients. Conclusion: The weekly administration of gemcitabine combined with 5-fluorouracil bolus iv is an active and well-tolerated regimen in metastatic pancreatic cancer. However, its efficacy is relatively limited.
URI: https://doi.org/10.1177/030089160409000206
https://journals.sagepub.com/doi/abs/10.1177/030089160409000206
http://hdl.handle.net/11452/27171
ISSN: 0300-8916
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Kanat_vd_2004.pdf660.89 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons